Molecular-targeted anticancer therapy: Challenges related to study design and choice of proper endpoints

Cancer Journal

Volumn 6, Issue 3, 2000, Pages 117-131

  Gasparini, Giampietro ^a   Gion, Massimo ^b  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b ULSS 12   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; FARNESYL DIPHOSPHATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN BINDING PROTEIN 3; TRASTUZUMAB; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; CANCER CELL; CANCER GROWTH; CANCER INVASION; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; HUMAN; MALIGNANT TRANSFORMATION; METASTASIS; NEUROTOXICITY; ONCOGENE NEU; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW;

ALKYL AND ARYL TRANSFERASES; ALLELES; BIOLOGICAL MARKERS; CLINICAL TRIALS; DNA-BINDING PROTEINS; ENDOTHELIAL GROWTH FACTORS; GENE THERAPY; HUMANS; LYMPHOKINES; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RESEARCH; RNA; TELOMERASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033914016     PISSN: 15289117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Renan MJ. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinogenesis 1993;7:139-146.
3. Lengauer C, Kinzler KW, Volgestein B. Genetic instabilities in human cancers. Nature 1998;396:643-649.
4. Nurse P. A long twentieth century of the cell cycle and beyond. Cell 2000;100:71-78.
5. Hahn WC, Counter CM, Lundberg AS et al. Creation of human tumor cells with defined genetic elements. Nature 1999;400:464-468.
6. Bieche I, Nogues C, Paradis V et al. Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000;6:452-459.
7. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-28.
8. Loeb LA. Mutator phenotype may be required for multistep carcinogenesis. Cancer Res 1991;51:3073-3079.
9. Kinzler KW, Volgestein B. Landscaping the cancer terrain. Science 1998;280:1036-1037.
10. Golub TR, Slonim DK, Tamayo P et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;86:531-537.
11. Califano J, Westra WH, Meininger G et al. Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin Cancer Res 2000;6:347-352.
12. Shoemaker RH. Genetic and epigenetic factors in anticancer drug resistance. J Natl Cancer Inst 2000;92:4-5.
13. Denko N, Schindler C, Koong A et al. Epigenetic regulation of gene expression in cervical cancer cells by the tumor microenvironment. Clin Cancer Res 2000;6:480-487.
14. Braverman AS. Chemotherapeutic failure: resistance or insensitivity? Ann Intern Med 1993;118:630-632.
15. Bradshaw DM, Arceci RJ. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 1998;16:3674-3690.
16. Caldas C. Molecular assessment of cancer. BMJ 1998; 316:1360-1363.
17. Lane D. The promise of molecular oncology. Lancet 1998;351:17-20.
18. Gelmon KA, Eisenhauer EA, Harris AL et al. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst 1999;91:1281-1287.
19. Bartelink H, Begg AC, Martin JC et al. Translational research offers individually tailored treatments for cancer patients. Cancer J Sci Am 2000;6:2-10.
20. Mao L. Can molecular assessment improve classification of head and neck premalignancy? Clin Cancer Res 2000;6: 321-322.
21. Harari PM, Huang S-M. Modulation of molecular targets to enhance radiation. Clin Cancer Res 2000;6:323-325.
22. Frankel AE, Kreitman RJ, Sausville EA. Targeted toxins. Clin Cancer Res 2000;6:326-334.
23. Kleyn PW, Vesell ES. Genetic variation as a guide to drug development. Science 1998;281:1820-1821.
24. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
25. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
26. Gasparini G. Antiangiogenic drugs as a novel anticancer therapeutic strategy. Which are the more promising agents? What are the clinical developments and indications? Crit Rev Oncol Hematol 1997;26:147-162.
27. Gasparini G. The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs 1999;58:17-38.
28. Libutti SK, Choyke P, Carrasquillo JA et al. Monitoring response to antiangiogenic agents using noninvasive imaging tests. Cancer J Sci Am 1999;5:252-256.
29. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-153.
30. Kakeji Y, Teicher BA. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 1997;15:39-48.
31. Baselga J, Norton L, Albanell J et al. Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825-2831.
32. Rowinsky E, Windle JJ, Von Hoff DD. Ras protein farnesyl-transferase: a strategic target for anticancer therapeutic development. J Clin Oncol 1999;17:3631-3652.
33. Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Semin Oncol 1999;26:71-77.
34. Gasparini G, Harris AL. Does improved control of tumour growth require an anti-cancer therapy targeting both neoplastic and intratumoral endothelial cells? Eur J Cancer 1994;30A:201-206.
35. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-1467.
36. Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 1993;85:1206-1219.
37. Gasparini G. Prognostic variables in node-negative breast cancer. Breast Cancer Res Treat 1998;52:321-331.
38. Cavalli F, Sessa C. Current issues in phase I trials: new study designs and informed consent procedures. Ann Oncol 1999;10:147-148.
39. Eisenhauer EA, O'Dwyer PJ, Christian M et al. Phase I clinical trial design in cancer drug development. J Clin Oncol 2000;18:684-692.
40. Cheng JD, Hitt J, Koczwara B et al. Impact of quality of life on patient expectations regarding phase I clinical trials. J Clin Oncol 2000;18:421-428.
41. Simon R, Freidlin B, Rubinstein L et al. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997;89:1138-1147.
42. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 1990;46:33-48.
43. O'Quigley J. Estimating the probability of toxicity at the recommended dose following a phase I clinical trial in cancer. Biometrics 1992;48:853-862.
44. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med 1995;14:1149-1161.
45. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep 1985;69:1375-1381.
46. Therasse P, Arbuck SG, Elisenhauer FLA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
47. Gehan E, Tefft MC. Will there be resistance to the RECIST (response evaluation criteria in solid tumors)? J Natl Cancer Inst 2000;92:179-181.
48. Mariani L, Marubini E. Content and quality of currently published phase II cancer trials. J Clin Oncol 2000;18:429-436.
49. Gasparini G. Prognostic value of vascular endothelial growth factor (VEGF) in breast cancer.The Oncologist 2000;5[suppl 1]: 37-44.
50. Gasparini G, Barbareschi M, Boracchi P et al. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy. Cancer J Sci Am 1995;1:131-141.
51. Gasparini G, Toi M, Gion M et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997;9:139-147.
52. Gasparini G, Toi M, Miceli R et al. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer J Sci Am 1999;5:101-111.
53. Locopo N, Fanelli M, Gasparini G. Clinical significance of angiogenic factors in breast cancer. Breast Cancer Res Treat 1998;52:159-173.
54. Carter P, Presta L, Gorman CM et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992;89:4285-4289.
55. Mendelsohn J, Baselga J. Antibodies to growth factors and receptors. In: De Vita VT, Hellman S, Rosemberg SA, eds. Biologic Therapy of Cancer (2nd ed). Philadelphia: JB Lippincott, 1995:607-624.
56. HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-2671.
57. HER2 monoclonal antibody in patients with HER2/neu-overxpressing metastatic breast cancer. J Clin Oncol 1996;14: 737-744.
58. Baselga J, Cooper MR, Cohen R et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-914.
59. 1. Cancer Res 2000;60:560-565.
60. Wu X, Rubin M, Fan Z et al. Involvement of p27kip1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 1996;12:1397-1403.
61. Peng D, Fan Z, Lu Y et al. Anti-epidermal growth factor receptor monoclonal antibody C225 upregulates p27kip1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 1996;56:3666-3669.
62. Fan Z, Shang BY, Lu Y et al. Reciprocal changes in p27kip1 and p21cip1 in growth inhibition mediated by blockade or overexpression of epidermal growth factor receptor. Clin Cancer Res 1997;3:1943-1948.
63. Fan Z, Baselga J, Masui H et al. Antitumor effects of antiepidermal growth factor receptor monoclonal antibodies plus cisdiamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993;53:4637-4642.
64. Baselga J, Norton L, Masui H et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factors receptor monoclonal antibodies. J Natl Cancer Inst 1993; 85:1327-1333.
65. Baselga J, Norton L, Coplan K et al. Antitumor activity of paclitaxel in combination with anti-growth factor receptor monoclonal antibodies in breast cancer xenografts. Proc Am Assoc Cancer Res 1994;35:2262.
66. Pegram MD, Konecny G, Slamon DJ. Use of HER2 for predicting response to breast cancer therapy. In: Harris JR, Lippman ME, eds. Diseases of the Breast. Updates Philadelphia: Lippincott-Raven, 1999;4:1-9.
67. Dowsett M, Cooke T, Ellis I et al. Assessment of HER2 status in breast cancer: why, when and how? Eur J Cancer 2000;36:170-176.
68. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-4689.
69. Shimizu K, Goldfarb M, Suard Y et al: Three human transforming genes are related to the viral oncogenes. Proc Natl Acad Sci USA 1983;80:2112-2116.
70. Nagasu T, Yoshimatsu K, Rowell C et al. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res 1995;55:5310-5314.
71. Miyake M, Mizutani S, Koide H et al: Unfarnesylated transforming Ras mutant inhibits the Ras-signaling pathway by forming a stable Ras.Raf complex in the cytosol. FEBS Lett 1992;378:15-18.
72. Kohl NE, Omer CA, Conner MW et al: Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1995;1:792-797.
73. Ward R, Hawkins N, O' Grady R et al. Restriction endonuclease-mediated selective polymerase chain reaction: a novel assay for the detection of K-ras mutations in clinical samples. Am J Pathol 1998;153:373-379.
74. Peli J, Schroter M, Rudaz C et al. Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas. Embo J 1999;18:1824-1831.
75. Zujewski J, Horak ID, Bol CJ et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2000;18:927-941.
76. Mosselman S, Polman J, Dijkema R. ERβ: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996;392:49-53.
77. Pfeffer U, Fecarotta E, Vidali G. Coexpression of multiple estrogen receptor variant messenger RNAs in normal and neoplastic breast tissues and in MCF-7 cells. Cancer Res 1995;55:2158-2165.
78. Horowitz KB, Jackson TA, Bain DL et al. Nuclear receptor coactivators and corepressor. Mol Endocrinol 1996; 10:1167-1177.
79. Kato S, Endoh H, Masuhiro Y et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-1494.
80. Zwijsen RM, Buckle RS, Hijmans EM et al. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev 1998;12:3488-3498.
81. Levenson AS, Jordan VC. Selective oestrogen receptor modulation: molecular pharmacology for the millennium. Eur J Cancer 1999;35:1628-1639.
82. Press MF, Hung G, Godolphin W et al. Sensitivity of HER2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-2777.
83. Dittadi R, Meo S, Amoroso B et al. Detection of different estrogen receptor forms in breast cancer cytosol by enzyme immunoassay. Cancer Res 1997;57:1066-1072.
84. Molecular Pathology Inspection Checklist, 1993 edition. Commission on Laboratory Accreditation. College of American Pathologists, 325 Waukegan Rd, Northfield, IL 60093.
85. Bolufer-Gilabert P, Barragan-Gonzalez E, Lopez-Guerrero JA. Could the water used in polymerase chain reaction be the cause of false positive results? Eur J Clin Chem Clin Biochem 1996;34:845.
86. Neumaier M, Braun A, Wagener C et al. Fundamentals of quality assessment of molecular amplification methods in clinical diagnostics. Clin Chem 1998;44:12-26.
87. EORTC Breast Cooperative Group. Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second EORTC Workshop, held on 16-17 March 1979, in the Netherlands Cancer Institute. Eur J Cancer 1980;16:1513-1535.
88. Sweep CGJ, Geurts-Moespot J, Grebenschikov N et al. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer 1998;78:1434-1441.
89. de Witte JH, Sweep CGJ, Klijn JGM et al. Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer. Br J Cancer 1999;80:286-294.
90. Altman DG, Lausen B, Sauerbrei W et al. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994;86:829-835.
91. Toi M, Gion M, Biganzoli E et al. Co-determination of the angiogenic factots thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: prognostic implications. Angiogenesis 1997;1:71-83.
92. Dittadi R, Biganzoli E, Boracchi P et al. Impact of steroid receptors, pS2 and cathepsin D on the outcome of N+ postmenopausal breast cancer patients treated with tamoxifen. Int J Biol Markers 1998;13:30-41.
93. Coradini D, Biganzoli E, Boracchi P et al. Effect of steroid receptors, pS2 and cathepsin D on the outcome of elderly breast cancer patients: an exploratory investigation. Int J Cancer 1998;79:305-311.
94. Bouchet C, Hacene K, Martin PM et al. Dissemination risk index based on plasminogen activator system components in primary breast cancer. J Clin Oncol 1999; 17:3048-3057.
95. Biganzoli E, Boracchi P, Daidone MG et al. Flexible modelling in survival analysis: structuring biological complexity from the information provided by tumor markers. Int J Biol Markers 1998;13:107-123.
96. Altman DG, De Stavola BL, Love SB et al. Review of survival analyses published in cancer journals. Br J Cancer 1995;72:511-518.
97. Temple RJ. A regulatory authority's opinion about surrogate endpoints. In: Nimmo WS, Tucker GT, eds. Clinical Measurement in Drug Evaluation. New York: J Wiley, 1995.
98. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125: 605-613.
99. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-440.
100. Lin DY, Fleming TR, De Gruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med 1997;16:1515-1527.
101. Moher D. CONSORT: an evolving tool to help improve the quality of reports of randomized trials. JAMA 1998; 279:1489-1491.
102. Horton R. Medical editors trial amnesty: unreported trial registration form. Lancet 1997;350:756-757.
103. Hayes DF, Bast RC, Desch CE et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-1466.
104. Gion M, Boracchi P, Biganzoli E et al. A guide for reviewing submitted manuscripts and indications for the design of translational research studies on biomarkers. Int J Biol Markers 1999;13:123-133.
105. Gasparini G, Presta M. Clinical studies with angiogenesis inhibitors: biological rationale and challenges for their evaluation. Ann Oncol 1996;7:441-444.
106. Barnes DM, Miles DW. Response of metastatic breast cancer to trastuzumab? Lancet 2000;355:160-161.
107. Hudes G, Schol J, Baab J et al. Phase I clinical and pharmacokinetic trial of the farnesyltransferase inhibitor R115777 on a 21-day dosing schedule. Proc Am Soc Clin Oncol 1999;18:156a.
108. Brown MJ. The hypoxic cell: a target for selective cancer therapy: eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 1999;59:5863-5870.
109. Koong AC, Denko NC, Hudson KM et al. Candidate genes for the hypoxic tumor phenotype. Cancer Res 2000;60:883-887.
110. Kimura H, Weisz A, Kurashima Y et al. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 2000;95:189-197.
111. Prenzel N, Zwick E, Daub H et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999;402:884-888.
112. Sanchez Y, Bachant J, Wang H et al. Control of the DNA damage checkpoint by Chk1 and Rad53 protein kinases through distinct mechanisms. Science 1999;286: 1166-1171.
113. Hirao A, Kong Y-Y, Matsuoka F et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 2000;287:1824-1827.
114. Car AM. Piecing together the p53 puzzle. Science 2000; 287:1765-1766.
115. de Lange T, Jacks T. For better or worse? Telomerase inhibition and cancer. Cell 1999;98:273-275.
116. Rudolph KL, Chang S, Lee H-W et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 1999;96:701-712.